The majority of HER2 somatic mutations in breast cancer patients are activating mutations that likely drive tumorigenesis with an overall HER2 mutation rate of approximately 1.6% in breast cancers without HER2 amplification [43]. This evidence concerns the gene ERBB2 and breast cancer.